Literature DB >> 19941446

Adipose tissue derived stem cells for regeneration and differentiation into insulin-producing cells.

Song Cheol Kim1, Duck Jong Han, Ji Yeon Lee.   

Abstract

Stem cells are considered an ideal tool for the supply of insulin-producing cells or repairing damaged pancreatic tissues to treat diabetes mellitus, with the possibility of unlimited sources. This cell population includes embryonic, adult bone marrow, pancreatic stem cells, extra pancreatic (such as hepatic cells) and adipose-derived stem cells. Multipotent adipose tissue-derived stem cells (ADSCs) are abundant in the human body, and thus are an ideal donor source for autologous transplantation to generate insulin-producing cells. Moreover these cells are better sources than bone marrow stem cells (BMSCs) for clinical applications, owing to minimal invasive procedures, high proliferation and multi-differentiation potential. Human adipose tissue-derived stem cells (hADSCs) may thus provide an alternative stem cell source, replacing BM-MSCs or embryonic stem cells (ESCs) for future clinical use in diabetes mellitus treatment.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19941446     DOI: 10.2174/157488810791268717

Source DB:  PubMed          Journal:  Curr Stem Cell Res Ther        ISSN: 1574-888X            Impact factor:   3.828


  9 in total

Review 1.  The potential of adipose stem cells in regenerative medicine.

Authors:  Bettina Lindroos; Riitta Suuronen; Susanna Miettinen
Journal:  Stem Cell Rev Rep       Date:  2011-06       Impact factor: 5.739

2.  Improving the efficacy of type 1 diabetes therapy by transplantation of immunoisolated insulin-producing cells.

Authors:  Phan Kim Ngoc; Pham Van Phuc; Truong Hai Nhung; Duong Thanh Thuy; Nguyen Thi Minh Nguyet
Journal:  Hum Cell       Date:  2011-05-13       Impact factor: 4.174

3.  Automated enumeration and viability measurement of canine stromal vascular fraction cells using fluorescence-based image cytometry method.

Authors:  Leo Li-Ying Chan; Donald A Cohen; Dmitry Kuksin; Benjamin D Paradis; Jean Qiu
Journal:  J Fluoresc       Date:  2014-04-17       Impact factor: 2.217

4.  In vitro preconditioning of insulin-producing cells with growth factors improves their survival and ability to release insulin.

Authors:  Muhammad Sohail Anjum; Azra Mehmood; Faiza Mahmood; Muhammad Ali; Moazzam Nazir Tarrar; Shaheen N Khan; Sheikh Riazuddin
Journal:  J Biosci       Date:  2018-09       Impact factor: 1.826

Review 5.  (Re)generating Human Beta Cells: Status, Pitfalls, and Perspectives.

Authors:  Luc Baeyens; Marie Lemper; Willem Staels; Sofie De Groef; Nico De Leu; Yves Heremans; Michael S German; Harry Heimberg
Journal:  Physiol Rev       Date:  2018-07-01       Impact factor: 37.312

Review 6.  Adipose tissue-derived stem cells: a comparative review on isolation, culture, and differentiation methods.

Authors:  Saber Khazaei; Ghazal Keshavarz; Azam Bozorgi; Hamed Nazari; Mozafar Khazaei
Journal:  Cell Tissue Bank       Date:  2021-02-22       Impact factor: 1.522

7.  Correction of Diabetic Hyperglycemia and Amelioration of Metabolic Anomalies by Minicircle DNA Mediated Glucose-Dependent Hepatic Insulin Production.

Authors:  Tausif Alam; Philip Wai; Dustie Held; Sahar Taba Taba Vakili; Erik Forsberg; Hans Sollinger
Journal:  PLoS One       Date:  2013-06-27       Impact factor: 3.240

8.  Promoting long-term survival of insulin-producing cell grafts that differentiate from adipose tissue-derived stem cells to cure type 1 diabetes.

Authors:  Shuzi Zhang; Hehua Dai; Ni Wan; Yolonda Moore; Zhenhua Dai
Journal:  PLoS One       Date:  2011-12-28       Impact factor: 3.240

Review 9.  Mesenchymal stem/stromal cells: a new ''cells as drugs'' paradigm. Efficacy and critical aspects in cell therapy.

Authors:  Laura de Girolamo; Enrico Lucarelli; Giulio Alessandri; Maria Antonietta Avanzini; Maria Ester Bernardo; Ettore Biagi; Anna Teresa Brini; Giovanna D'Amico; Franca Fagioli; Ivana Ferrero; Franco Locatelli; Rita Maccario; Mario Marazzi; Ornella Parolini; Augusto Pessina; Maria Luisa Torre
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.